Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
IPO Year: 2017
Exchange: AMEX
Website: zomedica.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/6/2023 | $6.00 | Buy | Dawson James |
SC 13G/A - Zomedica Corp. (0001684144) (Subject)
Dawson James initiated coverage of Zomedica Pharmaceuticals with a rating of Buy and set a new price target of $6.00
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2024."We are pleased with the progress in the quarter, which represents the highest second quarter for the Company to date. We saw significant growth in our diagnostic product revenue, reflecting growing adoption of our TRUFORMA® and VETGuardian® products. We also enjoyed substantial growth in consumable products, reflecting the robust usage of ou
ANN ARBOR, MI / ACCESSWIRE / August 1, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Wednesday, August 14, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its second quarter ended June 30, 2024. A question-and-answer session will follow management's prepared remarks.Event: Zomedica Corp. Q2 2024 Financial Results Conference CallDate: Wednesday, August 14, 2024Time: 4:30 p.m. Eastern TimeLive Call: +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (International
Performance Sets New Record for First Quarter RevenueANN ARBOR, MI / ACCESSWIRE / May 9, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2024.2024 First Quarter Financial HighlightsRevenue for the first quarter of 2024 grew 14% to $6.3 million, compared to first quarter 2023 revenue, driven by 9% growth over the prior year in the Therapeutic Devices segment and 86% growth over the prior year in the Diagnostics segment.Consumable revenues grew to $4.0 million, up 7% over firs
ANN ARBOR, MI / ACCESSWIRE / April 30, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, May 9th, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its first quarter ended March 31, 2024. A question-and-answer session will follow management's prepared remarks.Event: Zomedica Corp. Q1 2024 Financial Results Conference CallDate: Thursday, May 9th, 2024Time: 4:30 p.m. Eastern TimeLive Call: +1-888-886-7786 (U.S. Toll-Free) or +1-416-764-8658 (International)Webca
ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic device products for equine and companion animals, today reported consolidated financial results for the fourth quarter and year-ended December 31, 2023. All figures are in US dollars unless otherwise stated."The fourth quarter capped off another record quarter and year for Zomedica. On the strength of our highest revenue quarter ever, we grew full year revenue by over 33%, due to early adoption of newly launched products in our Diagnostics segment, and continued strength in our Therapeutic Devices segment," comment
ANN ARBOR, MI / ACCESSWIRE / March 20, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Monday, April 1st, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its fourth quarter and full year ended December 31, 2023. A question-and-answer session will follow management's prepared remarks.Event: Zomedica Corp. Q4 and Full Year 2023 Financial Results Conference CallDate: Monday, April 1, 2024Time: 4:30 p.m. Eastern TimeLive Call: +1-877-407-0789 (U.S. Toll-Free) or +1-201
ANN ARBOR, MI / ACCESSWIRE / January 17, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today provided a business update and will be hosting a conference call.Fourth Quarter Financial HighlightsRevenue for the fourth quarter of 2023 is expected to be over $7 million, a new record for the Company, compared to record fourth quarter 2022 revenue of $6.2 million, primarily driven by strong performance across many product lines, highlighted by a record quarter in the Therapeutic Device segment.Full Year 2023 Financial HighlightsRevenue for 2023 is expected to
ANN ARBOR, MI / ACCESSWIRE / January 10, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that it will be hosting a conference call on Wednesday, January 17, 2024 at 4:30 p.m. ET.Management will provide a business update, including preliminary 2023 revenue and cash position, as well as other operational highlights during the call. In addition, the Company will discuss the upcoming Share Consolidation ("reverse stock split") and other matters related to a Special Virtual-Only Meeting of Shareholders to be held on February 28, 2024, at 1:00 p.m
ANN ARBOR, MI / ACCESSWIRE / November 13, 2023 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported consolidated financial results for the quarter ended September 30, 2023.2023 Third Quarter Financial HighlightsRevenues for the third quarter of 2023 grew 31% to $6.3 million, compared to third quarter 2022 revenues of $4.8 million, primarily driven by:Growth in the Therapeutic Devices segment, where revenues from PulseVet® and Assisi® product sales came in at $6.0 million, reflecting an increase of 28% over third quarter 2022 revenues;Growth in the Diagnostic seg
ANN ARBOR, MI / ACCESSWIRE / November 2, 2023 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Monday, November 13, 2023 at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its third quarter ended September 30, 2023. A question-and-answer session will follow management's prepared remarks.Event: Zomedica Q3 2023 Financial Results Conference CallDate: Monday, November 13, 2023Time: 4:30 p.m. Eastern TimeLive Call: +1-877-407-0789 (U.S. Toll-Free) or +1-201-689-8562 (International)Webcast: http
Expansion adds new countries to Grovet's existing PulseVet distribution coverage and enables launch of the TRUFORMA® equine platform in Europe ANN ARBOR, MI / ACCESSWIRE / October 3, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the expansion of its distribution partnership in Europe with Grovet, a leading equine-focused veterinary distributor.The terms of the updated agreement offer Grovet equine distribution rights for Zomedica's equine PulseVet® and TRUFORMA product platforms throughout most of Europe. Grovet will exclusively distribut
Expanded cleanroom and improved distribution facilities enhance manufacturing capacity and shipping efficiencies ANN ARBOR, MI / ACCESSWIRE / September 11, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, is pleased to announce the completion of renovations at its 30,000-square-foot manufacturing, distribution, and research and development (R&D) facility in Plymouth, Minnesota.Highlights of the renovation include:Expanded cleanroom for manufacturing operationsInstallation and validation of new automated line to produce TRUFORMA® consumable cartridgesImproved distribution
CE Mark approval opens European market for TRUVIEW system ANN ARBOR, MI / ACCESSWIRE / September 5, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced it has secured the CE Mark for its revolutionary TRUVIEW™ digital microscopy and telepathology platform. The CE Mark certification affirms the system's compliance with the stringent health, safety, and environmental standards required by the European Union, enabling Zomedica to commercialize the TRUVIEW microscope across the European Economic Area (EEA).The TRUVIEW platform integrates advanced d
Assisi's tPEMF™ technology aligns with Fear Free's mission to “prevent and alleviate fear, anxiety, and stress in pets” ANN ARBOR, MI / ACCESSWIRE / August 29, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering therapeutic and diagnostic products for equine and companion animals, is pleased to announce that its Assisi Loop® product line is continuing its designation as a Fear Free Preferred Product. Fear Free, a globally recognized initiative dedicated to reducing fear, anxiety, and stress in pets, reaffirmed its validation of Assisi's targeted pulsed electromagnetic field (tPEMF) technology, which is designed to reduce inflammati
Increased functionality makes the VETGuardian system a must have for veterinarians ANN ARBOR, MI / ACCESSWIRE / August 22, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company", a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, announced the introduction of advanced audio capabilities for its VETGuardian Zero-touch remote vital signs monitoring system, poised to revolutionize remote patient monitoring in veterinary medicine. These cutting-edge features include real-time audio streaming, recorded playback functionality, and customizable alerts, empowering veterinarians with unparalleled insights into animal health
Increased functionality makes the VETGuardian system a must have for veterinarians ANN ARBOR, MI / ACCESSWIRE / August 22, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company", a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, announced the introduction of advanced audio capabilities for its VETGuardian Zero-touch remote vital signs monitoring system, poised to revolutionize remote patient monitoring in veterinary medicine. These cutting-edge features include real-time audio streaming, recorded playback functionality, and customizable alerts, empowering veterinarians with unparalleled insights into animal health
Leading veterinary experts to present at the Fetch dvm360 Veterinary Conference in Kansas City, August 23-25, 2024 ANN ARBOR, MI / ACCESSWIRE / August 20, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced its sponsorship of educational programs at the upcoming Fetch dvm360 Veterinary Conference, taking place in Kansas City, MO, from August 23-25, 2024."We are proud to continue our partnership with the Fetch dvm360 series of veterinary Continuing Education programs," commented Nicole Westfall, Zomedica's Senior Vice President of Marketing. "The
Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2024."We are pleased with the progress in the quarter, which represents the highest second quarter for the Company to date. We saw significant growth in our diagnostic product revenue, reflecting growing adoption of our TRUFORMA® and VETGuardian® products. We also enjoyed substantial growth in consumable products, reflecting the robust usage of ou
SIRE Veterinario, SA Selected as Distribution Partner to Launch Zomedica® Products into Costa Rica ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the latest expansion of its sales reach into Costa Rica. SIRE Veterinario, S.A. will be the exclusive distributor to veterinarians in the country, offering a range of Zomedica products as they become available in the region."We are further expanding our international reach by engaging with terrific partners, like SIRE Veterinario," stated Larry Heaton, Chie
ANN ARBOR, MI / ACCESSWIRE / August 1, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Wednesday, August 14, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its second quarter ended June 30, 2024. A question-and-answer session will follow management's prepared remarks.Event: Zomedica Corp. Q2 2024 Financial Results Conference CallDate: Wednesday, August 14, 2024Time: 4:30 p.m. Eastern TimeLive Call: +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (International
8-K - Zomedica Corp. (0001684144) (Filer)
8-K - Zomedica Corp. (0001684144) (Filer)
10-Q - Zomedica Corp. (0001684144) (Filer)
S-8 - Zomedica Corp. (0001684144) (Filer)
8-K - Zomedica Corp. (0001684144) (Filer)
8-K - Zomedica Corp. (0001684144) (Filer)
10-Q - Zomedica Corp. (0001684144) (Filer)
ARS - Zomedica Corp. (0001684144) (Filer)
DEFA14A - Zomedica Corp. (0001684144) (Filer)
DEF 14A - Zomedica Corp. (0001684144) (Filer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
4 - Zomedica Corp. (0001684144) (Issuer)
ANN ARBOR, MI / ACCESSWIRE / March 17, 2023 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Peter L. Donato as its Chief Financial Officer, effective March 16, 2023. Mr. Donato brings over 30 years of public and private company experience in a wide range of finance and business functions primarily in the human health sector, having held a number of senior positions from CFO, President and CEO, Executive Vice President, Senior Vice President, Vice President and Controller. Prior to joining Zomedica, Mr. Donato had a successful consulting
ANN ARBOR, MI / ACCESSWIRE / August 23, 2022 / Zomedica Corp. (NYSE:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Pamela Nichols, DVM has been appointed to its Board of Directors and is joining the Audit and Governance committees.Dr. Nichols is the founder of six successful veterinary hospitals and dog boarding/daycare facilities. Her newest hospital is Animal Care Daybreak in South Jordan Utah, which opened in October of 2019. She earned her doctorate in veterinary medicine at Colorado State University in 1996 and her Canine Rehabilitation Practitioner (CCRP) certification in 2004. She
ANN ARBOR, MI / ACCESSWIRE / June 2, 2022 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Karen DeHaan-Fullerton as its General Counsel and Corporate Secretary. She joined the Zomedica team on May 31, 2022.Ms. DeHaan-Fullerton joins the company with more than 20 years of corporate legal experience, including advising and leading companies through transformation and acquisition activities."Karen is a welcome addition to the Zomedica team, bringing a mix of executive leadership experience and business development knowledge," said Larry Heaton, Ch
ANN ARBOR, MI / ACCESSWIRE / February 15, 2022 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Adrian Lock, Vice President and General Manager, will lead the Company's sales organization, including Zomedica field sales personnel, sales management and professional service veterinarians, as well as existing PulseVet sales personnel.As the founding Chief Executive Officer of PulseVet, Mr. Lock led the company and personally directed all sales activities over the past decade as it established PulseVet shock wave therapy as a standard of care in equine sports medicine."I
ANN ARBOR, Mich., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that Larry Heaton has been appointed President effective October 1, 2021. Mr. Heaton will assume the role of Chief Executive Officer upon the retirement of current Chief Executive Officer Robert Cohen on October 31, 2021. Following his retirement, Mr. Cohen will remain on the Board of Directors of Zomedica. Mr. Heaton brings to Zomedica more than 35 years of executive leadership and operations experience from the medical device and biotechnology industries
FOCUSED ON TRUFORMA® INSTRUMENT PLACEMENTS AND BUILDING DIRECT SALES ORGANIZATION ANN ARBOR, Mich., July 06, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company creating point-of-care diagnostics products for dogs and cats, provided the following corporate update: As previously announced, Zomedica's flagship product – TRUFORMA® – is intended to have five initial assays to test for adrenal and thyroid disorders, which will be followed by many more assays to address other disease states. Three of the initial assays (TSH, tT4 and Cortisol) currently are available. While waiting for the completion of the fT4 and ACTH assays by its dev
Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, today announced the commercial launch of its second equine focused assay - Cortisol for equine serum - for the point-of-care TRUFORMA® diagnostic platform. "Cortisol measurement is crucial for assessing the health of sick foals and has never been available at the point of care until now," stated Dr. T.J. Barclay, a Professional Services Veterinarian for Zomedica. "Traditionally, equine veterinarians have had to send samples to reference labs and potentially wait several days for results - often receiving them too late to make cr
The Dow Jones index closed lower by around 0.2% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Aclaris Therapeutics The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard bought a total of 1,611,200 shares at an average price of $1.11. To acquire these shares, it cost around $1.78 million. What's Happening: On M
The firm announced the presentation of research highlighting the improved diagnostic capabilities of the TRUFORMA® Bulk Acoustic Wave (BAW) platform when evaluating cats for thyroid disease compared to widely utilized chemiluminescent immunoassay (CLIA) platforms.
The Dow Jones index closed higher by around 350 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Sabre The Trade: Sabre Corporation (NASDAQ:SABR) Executive Vice President Roshan Mendis bought a total of 31,067 shares at an average price of $3.15. To acquire these shares, it cost around $97,802. What's Happening: On May 2, Sabre reporte
The Dow Jones index closed lower by over 80 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Earth Science Tech The Trade: Earth Science Tech, Inc. (OTC:ETST) Director Yovan Arturo Sanchez bought a total of 10,500 shares at an average price of $0.10. To acquire these shares, it cost around $1,050. What's Happening: On Jan. 29, Earth Scien